Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06767462 | RECRUITING | Ophthalmic Safety in Patients With Breast Cancer

An Ophthalmic Safety Study in Patients With Breast Cancer
Sponsor:

AstraZeneca

Brief Summary:

To assess ophthalmic health in parallel cohorts of patients with breast cancer

Condition or disease

Ophthalmic Safety in Patients With Breast Cancer

Detailed Description:

This is a multicentre study assessing the ophthalmic safety in patients who are participating in a qualifying study. The study will include two cohorts of at least 60 individuals each. To be able to account for events associated with aging, worsening of pre-existing conditions, etc., ophthalmic study assessments will be performed in parallel in two cohorts at the same timepoints. The duration of the study assessment period will be approximately 12 months. Longer duration of the study would result in additional patient burden.

Study Type : OBSERVATIONAL
Estimated Enrollment : 160 participants
Official Title : A Multicentre Study Assessing Ophthalmic Safety in Patients With Breast Cancer
Actual Study Start Date : 2025-03-04
Estimated Primary Completion Date : 2027-07-06
Estimated Study Completion Date : 2027-07-06

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 130 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Signed informed consent in the qualifying study.
  • 2. Signed informed consent in the ophthalmic study prior to any ophthalmic study specific assessments and procedures.
  • 3. Completed the baseline ophthalmic examination for this study before the first dose in the qualifying study.
  • 4. Meets all the eligibility criteria in the qualifying study
Exclusion Criteria
  • 1. Patients not randomized and not receiving study assigned treatment in a qualifying study.
  • 2. Patients with contraindications to any ophthalmic procedure required by the study or sensitivity/allergy to pupil dilating agents.
  • 3. Judgement by the investigator that the patient should not participate in the ophthalmic study if the patient is unlikely to comply with study procedures, restrictions, and requirements
An Ophthalmic Safety Study in Patients With Breast Cancer

Location Details

NCT06767462

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

NOT YET RECRUITING

United States, California

Research Site

THE JOLLA, California, United States, 92093

NOT YET RECRUITING

United States, California

Research Site

Palo Alto, California, United States, 94304

NOT YET RECRUITING

United States, California

Research Site

San Diego, California, United States, 92123

NOT YET RECRUITING

United States, Iowa

Research Site

Iowa City, Iowa, United States, 52242

NOT YET RECRUITING

United States, New York

Research Site

New York, New York, United States, 10029

NOT YET RECRUITING

United States, North Carolina

Research Site

Winston-Salem, North Carolina, United States, 27104

NOT YET RECRUITING

United States, Ohio

Research Site

Cleveland, Ohio, United States, 44195

SUSPENDED

United States, Pennsylvania

Research Site

Clairton, Pennsylvania, United States, 15025

NOT YET RECRUITING

United States, Pennsylvania

Research Site

Pittsburgh, Pennsylvania, United States, 15219

NOT YET RECRUITING

United States, South Dakota

Research Site

Sioux Falls, South Dakota, United States, 57105

NOT YET RECRUITING

United States, Tennessee

Research Site

Bartlett, Tennessee, United States, 38133

NOT YET RECRUITING

United States, Texas

Research Site

Houston, Texas, United States, 77030

NOT YET RECRUITING

Argentina,

Research Site

Buenos Aires, Argentina, C1125ABD

WITHDRAWN

Argentina,

Research Site

Buenos Aires, Argentina, C1425AYC

NOT YET RECRUITING

Argentina,

Research Site

CABA, Argentina, 1061

NOT YET RECRUITING

Argentina,

Research Site

Cordoba, Argentina, 5008

NOT YET RECRUITING

Argentina,

Research Site

San Miguel de Tucuman, Argentina, T4000IAK

NOT YET RECRUITING

Argentina,

Research Site

San Miguel de Tucumán, Argentina, 4000

NOT YET RECRUITING

Belgium,

Research Site

Edegem, Belgium, 2650

RECRUITING

Belgium,

Research Site

Leuven, Belgium, 3000

RECRUITING

Belgium,

Research Site

Liege, Belgium, 4000

NOT YET RECRUITING

Brazil,

Research Site

Alfenas, Brazil, 37130-000

NOT YET RECRUITING

Brazil,

Research Site

Beautiful view, Brazil, 01321-001

NOT YET RECRUITING

Brazil,

Research Site

Belo Horizonte, Brazil, 30130-100

NOT YET RECRUITING

Brazil,

Research Site

Curitiba, Brazil, 80810-050

NOT YET RECRUITING

Brazil,

Research Site

Slab, Brazil, 95900000

NOT YET RECRUITING

Brazil,

Research Site

Porto Alegre, Brazil, 90035-001

NOT YET RECRUITING

Brazil,

Research Site

Porto Alegre, Brazil, 90050-170

NOT YET RECRUITING

Brazil,

Research Site

Pouso Alegre, Brazil, 37554-216

NOT YET RECRUITING

Brazil,

Research Site

Rio de Janeiro, Brazil, 20560-120

NOT YET RECRUITING

Brazil,

Research Site

Sorocaba, Brazil, 18060-105

NOT YET RECRUITING

Brazil,

Research Site

Three lagoons, Brazil, 79601-001

NOT YET RECRUITING

Brazil,

Research Site

Vitoria, Brazil, 29055-450

NOT YET RECRUITING

Canada, Quebec

Research Site

Montreal, Quebec, Canada, H2X 3E4

NOT YET RECRUITING

Canada, Quebec

Research Site

Montreal, Quebec, Canada, H4A 3J1

NOT YET RECRUITING

Chile,

Research Site

Santiago, Chile, 7500587

NOT YET RECRUITING

Chile,

Research Site

Santiago, Chile, 7620157

WITHDRAWN

Chile,

Research Site

Santiago, Chile, 8331143

NOT YET RECRUITING

France,

Research Site

Bordeaux Cedex, France, 33077

NOT YET RECRUITING

France,

Research Site

Caen, France, 14000

WITHDRAWN

France,

Research Site

Nantes, France, 44202

NOT YET RECRUITING

France,

Research Site

Poitiers, France, 86021

NOT YET RECRUITING

France,

Research Site

Suresnes Cedex, France, 92151

RECRUITING

Israel,

Research Site

Ashdod, Israel, 7747629

NOT YET RECRUITING

Israel,

Research Site

Raisa, Israel, 2210001

NOT YET RECRUITING

Italy,

Research Site

Milano, Italy, 20132

WITHDRAWN

Korea, Republic of,

Research Site

Busan, Korea, Republic of, 48108

WITHDRAWN

Korea, Republic of,

Research Site

Daegu, Korea, Republic of, 41931

NOT YET RECRUITING

Korea, Republic of,

Research Site

Seoul, Korea, Republic of, 6351

NOT YET RECRUITING

Mexico,

Research Site

Aguascalientes, Mexico, 20230

NOT YET RECRUITING

Mexico,

Research Site

CDMX, Mexico, 03810

NOT YET RECRUITING

Mexico,

Research Site

San Pedro Garza Garcia, Mexico, 66220

NOT YET RECRUITING

Mexico,

Research Site

Veracruz, Mexico, 91851

NOT YET RECRUITING

Poland,

Research Site

New Sol, Poland, 67-106

NOT YET RECRUITING

Portugal,

Research Site

Amateur, Portugal, 2720-276

NOT YET RECRUITING

Portugal,

Research Site

Braga, Portugal, 4710-243

WITHDRAWN

Portugal,

Research Site

Lisboa, Portugal, 1998-018

NOT YET RECRUITING

Spain,

Research Site

Badalona, Spain, 08003

NOT YET RECRUITING

Spain,

Research Site

Barcelona, Spain, 08028

NOT YET RECRUITING

Spain,

Research Site

Barcelona, Spain, 08035

NOT YET RECRUITING

Spain,

Research Site

Barcelona, Spain, 08036

NOT YET RECRUITING

Spain,

Research Site

L'Hospitalet de Llobregat, Spain, 08908

NOT YET RECRUITING

Spain,

Research Site

Leganes, Spain, 28911

NOT YET RECRUITING

Spain,

Research Site

Madrid, Spain, 28007

NOT YET RECRUITING

Spain,

Research Site

Madrid, Spain, 28009

NOT YET RECRUITING

Spain,

Research Site

Madrid, Spain, 28033

NOT YET RECRUITING

Spain,

Research Site

Madrid, Spain, 28034

NOT YET RECRUITING

Spain,

Research Site

Madrid, Spain, 28040

NOT YET RECRUITING

Spain,

Research Site

Madrid, Spain, 28041

NOT YET RECRUITING

Spain,

Research Site

Madrid, Spain, 28050

NOT YET RECRUITING

Spain,

Research Site

Majadahonda, Spain, 28222

NOT YET RECRUITING

Spain,

Research Site

Salamanca, Spain, 37007